Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.

Franklin Genomic Advancements Fund I (acc) EUR Fonds 113697910 / LU2387456671

6.79 EUR
-0.05 EUR
-0.73 %
6.2.2025
NAV

Nettoinventarwert (NAV)

6.79 EUR -0.05 EUR -0.73 %
Vortag 6.84 EUR Datum 06.02.2025

Franklin Genomic Advancements Fund I (acc) EUR Fonds Kurs - 1 Jahr

  • 1W
  • 3M
  • 1J
  • 3J
  • 5J
  • MAX

Top Kryptowährungen ETPs

Name ISIN Performance
21Shares Ripple XRP ETP CH0454664043 333.34%
21Shares Stellar ETP CH1109575535 230.41%
21Shares Stacks Staking ETP CH1258969042 227.84%
21Shares The Sandbox ETP CH1177361008 134.26%
21Shares Algorand ETP CH1146882316 123.50%
21Shares Sui Staking ETP CH1360612159 49.98%
21Shares Injective Staking ETP CH1360612134 -19.81%
21Shares Immutable ETP CH1360612142 -25.70%
Name ISIN Performance
21Shares Sui Staking ETP CH1360612159 519.85%
21Shares Ripple XRP ETP CH0454664043 346.24%
21Shares Stellar ETP CH1109575535 246.54%
21Shares Stacks Staking ETP CH1258969042 145.10%
21Shares Aave ETP CH1135202120 136.29%
21Shares Algorand ETP CH1146882316 132.00%
21Shares Injective Staking ETP CH1360612134 -9.38%
21Shares Immutable ETP CH1360612142 -22.72%
Name ISIN Performance
21Shares Ripple XRP ETP CH0454664043 348.33%
21Shares Aave ETP CH1135202120 188.19%
21Shares Stellar ETP CH1109575535 187.88%
21Shares Crypto Basket Equal Weight (HODLV) ETP CH1135202161 172.97%
21Shares Bitcoin Core ETP CH1199067674 124.82%
Name ISIN Performance
21Shares Solana staking ETP CH1114873776 748.23%
21Shares Ripple XRP ETP CH0454664043 452.06%
21Shares Bitcoin Core ETP CH1199067674 320.93%
21Shares Bitcoin ETP CH0454664001 310.28%
21Shares Crypto Basket Equal Weight (HODLV) ETP CH1135202161 270.16%

Fundamentaldaten

Valor 113697910
ISIN LU2387456671
Emittent Franklin Templeton International Services
Aufgelegt in Luxembourg
Auflagedatum 15.10.2021
Kategorie Branchen: Gesundheitswesen
Währung EUR
Volumen 3’011’165.14
Depotbank J.P. Morgan SE, Luxembourg Branch
Geschäftsjahresende 30.06.
Berichtsstand 04.02.2025

Anlagepolitik

So investiert der Franklin Genomic Advancements Fund I (acc) EUR Fonds: The Fund's investment objective is capital appreciation. The Fund invests principally in equity securities of companies that are relevant to the Fund’s investment theme of genomic advancements. Equity securities generally entitle the holder to participate in a company's general operating results. While the Fund invests predominantly in common stocks, it could also invest in preferred stock, convertible securities and warrants on securities.

ETP Performance: Franklin Genomic Advancements Fund I (acc) EUR Fonds

Performance 1 Jahr
3.82
Performance 2 Jahre
-1.02
Performance 3 Jahre
-13.72
Performance 5 Jahre -
Performance 10 Jahre -